MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/82.5/0.1/20.06.25 | Market Closed - Börse Stuttgart 17:52:08 14/06/2024 BST | ||
| 0.7 EUR | +1.45% |
|
| Current month | +14.75% | ||
| 1 month | +25.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 0.7 | +1.45% |
| 13/06/24 | 0.69 | -4.17% |
| 12/06/24 | 0.72 | +9.09% |
| 11/06/24 | 0.66 | -8.33% |
| 10/06/24 | 0.72 | +1.41% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 05:52 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | ME3JA6 |
| ISIN | DE000ME3JA65 |
| Date issued | 13/11/2023 |
| Strike | 82.5 $ |
| Maturity | 20/06/2025 (370 Days) |
| Parity | 10 : 1 |
| Emission price | 0.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.73 € |
|---|---|
| Lowest since issue | 0.1 € |
| Spread | 0.01 € |
| Spread % | 1.41% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6
USD
Average target price
174.4
USD
Spread / Average Target
+9.95%
- Stock Market
- Warrants
- Warrant